In vitro antifungal activity of voriconazole: New data after the first years of clinical experience;Actividad antifúngica in vitro de voriconazol: Nue vos datos después de los primeros años de experiencia clínica

Revista Iberoamericana de Micologia

Volumn 24, Issue 3, 2007, Pages 198-208

  Quindós, Guillermo ^a   Carrillo Muñoz, Alfonso Javier ^b   Eraso, Elena ^a   Cantón, Emilia ^c   Pemán, Javier ^c  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Associacio Catalana d'Intelligencia Artificial   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antifungal agents; Aspergillus; Candida; Cryptococcus; Dermatophytes; Fusarium; In vitro activity; Moulds; Scedosporium; Voriconazole; Yeasts

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BUPIVACAINE; CASPOFUNGIN; EQUINOCANDIN; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LIDOCAINE; MEVINOLIN; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ASPERGILLUS; BIOFILM; CANDIDA; CANDIDA GLABRATA; CANDIDIASIS; CHEMOSENSITIVITY; CLINICAL PRACTICE; CONCENTRATION RESPONSE; CROSS RESISTANCE; CRYPTOCOCCUS; DRUG POTENTIATION; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MOULD; MYCOSIS; NONHUMAN; REVIEW; SCEDOSPORIUM; YEAST;

ARTHRODERMATACEAE; ASPERGILLUS; CANDIDA; CANDIDA GLABRATA; FUNGI; FUSARIUM; SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS;

EID: 35348984571     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1130-1406(07)70043-8     Document Type: Review

References (162)

1. Adam B, Baillie GS, Douglas LJ. Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J Med Microbiol 2002; 51: 344-349.
2. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005; 80: 868-871.
3. Almirante B, Rodriguez D, Cuenca-Estrella M, Almela M, Sanchez F, Ayats J, Alonso-Tarres C, Rodriguez-Tudela JL, Pahissa A. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44: 1681-1685.
4. Antachopoulos C, Papakonstantinou E, Dotis J, Bibashi E, Tamiolaki M, Koliouskas D, Roilides E. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. J Pediatr Hematol Oncol 2005; 27: 283-285.
5. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 2006; 15: 579-602.
6. Araujo R, Pina-Vaz C, Rodrigues AG. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus. Int J Antimicrob Agents 2007; 29: 108-111.
7. Azanza JR, Garcia-Quetglás E, Sádaba B. Farmacología de los azoles. Rev Iberoam Micol 2007; 24: en prensa.
8. Bagg J, Sweeney MP, Davies AN, Jackson MS, Brailsford S. Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer. J Med Microbiol 2005; 54: 959-964.
9. Barchiesi F, Spreghini E, Maracci M, Fothergill AW, Baldassarri I, Rinaldi MG, Scalise G. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob Agents Chemother 2004; 48: 3317-3322.
10. Barnes PD, Marr KA. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am 2006; 20: 545-561.
11. Bassetti M, Trecarichi EM, Righi E, Sanguinetti M, Bisio F, Posteraro B, Soro O, Cauda R, Viscoli C, Tumbarello M. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007; en prensa.
12. Bhat SV, Paterson DL, Rinaldi MG, Veidkamp PJ. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J infect Dis 2007; 39: 87-90.
13. Borg-von ZM, Kunz L, Ruchel R, Reichard U, Weig M, Gross U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 2007; en prensa.
14. Borst A, Raimer MT, Warnock DW, Morrison CJ, Arthington-Skaggs BA. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother 2005; 49: 783-787.
15. Bouza E, Munoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect 2004; 10 (Supl. 1): 76-85.
16. Bouza E, Munoz P, Guinea J. Mucormycosis: an emerging disease? Clin Microbiol Infect 2006; 12 (Supl. 7): 7-23.
17. Cannizzo FT, Eraso E, Ezkurra PA, Villar-Vidal M, Bollo E, Castella G, Cabañes FJ, Vidotto V, Quindós G. Biofilm development by clinical isolates of Malassezia pachydermatis. Med Mycol 2007; 45: 357-361.
18. Cantón E, Pemán J, Bosch M, Viudes A, Gobernado M. Actividad del voriconazol sobre levaduras aisladas de hemocultivo determinada por dos métodos. Rev Esp Quimioter 2005; 18: 308-312.
19. Cantón E, Pemán J, Gobernado M, Viudes A, Espinel-Ingroff A. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother 2005; 49: 1593-1596.
20. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45: 2151-2153.
21. Carrillo-Muñoz AJ, Brio S, Quindós G. Una nueva generación de fàrmacos antifúngicos. Rev Iberoam Micol 2001; 18: 2-5.
22. Carrillo-Muñoz AJ, Cárdenes CD, Carrillo-Orive B, Rodríguez V, Del Valle O, Casals JB, Ezkurra PA, Quindós G. In vitro antifungal activity of voriconazole against dermatophytes and superficial isolates of Scopulariopsis brevicaulis. Rev Iberoam Micol 2005; 22: 110-113.
23. Carrillo-Muñoz AJ, Giusiano G, Ezkurra PA, Quindós G. Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter 2006; 19: 130-139.
24. Carrillo-Muñoz AJ, Giusiano G, Guarro J, Quindós G, Guardia C, Del Valle O, Rodríguez V, Estivill D, Cárdenes CD. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. Int J Antimicrob Agents 2007; en prensa.
25. Carrillo-Muñoz AJ, Pemán J, Gobernado M. Nuevos antifúngicos. Presente y futuro. Rev Esp Quimioter 1999; 12: 181-204.
26. Carrillo-Muñoz AJ, Quindós G, Gasser I, Tur-Tur C, Ruesga MT, Alonso-Vargas R, Arevalo P, Bornay-Llinares FJ, Santos P, Del Valle O. Determination mediante el sistema Sensititre® de la sensibilidad in vitro a los antifúngicos de levaduras de interés médico. Rev Esp Quimioter 1999; 12: 126-135.
27. Carrillo-Muñoz AJ, Quindós G, López-Ribot JL. Current developments in antifungal agents. Current Medicinal Chemistry - Anti-Infective Agents 2004; 3: 297-323.
28. Carrillo-Munoz AJ, Quindos G, Ruesga M, Del Valle O, Peman J, Canton E, Hernandez-Molina JM, Santos P. In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast One. Mycoses 2006; 49: 293-297.
29. Cernicka J, Subik J. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006; 27: 403-408.
30. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006; 50: 96-103.
31. Chandenier J, Adou-Bryn KD, Douchet C, Sar B, Kombila M, Swinne D, Therizol-Ferly M, Buisson Y, Richard-Lenoble D. In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis 2004; 23: 506-508.
32. Chandra J, Zhou G, Ghannoum MA. Fungal biofilms and antimycotics. Curr Drug Targets 2005; 6: 887-894.
33. Chang WN, Huang CR, Lei CB, Lee PY, Chien CC, Chang HW, Chang CS, Lu CH. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole. Jpn J Infect Dis 2004; 57: 113-115.
34. Christakis G, Perlorentzou S, Aslanidou M, Megalakaki A, Velegraki A. Fatal Blastoschizomyces capitatus sepsis in a neutropenic patient with acute myeloid leukemia: first documented case from Greece. Mycoses 2005; 48: 216-220.
35. Chryssanthou E, Cuenca-Estrella M. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841-3844.
36. Chryssanthou E, Cuenca-Estrella M. Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. Clin Microbiol Infect 2006; 12: 901-904.
37. Cordeiro RA, Brilhante RS, Rocha MF, Fechine MA, Costa AK, Camargo ZP, Sidrim JJ. In vitro activities of caspofungin, amphotericin B and azoles against Coccidioides posadasii strains from Northeast, Brazil. Mycopathologia 2006; 161: 21-26.
38. Costa CR, de Lemos JA, Passos XS, de Araujo CR, Cohen AJ, Souza LK, Silva MR. Species distribution and antifungal susceptibility profile of oral Candida isolates from HIV-infected patients in the antiretroviral therapy era. Mycopathologia 2006; 162: 45-50.
39. Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother 2006; 50: 2248-2250.
40. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, Alcazar-Fuoli L, Mellado E, Buitrago MJ, Rodriguez-Tudela JL. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 2005; 49: 1232-1235.
41. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-921.
42. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL. Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clin Microbiol Infect 2005; 11: 486-492.
43. Cuenca-Estrella M, Rodriguez D, Almirante B, Morgan J, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Salvado M, Warnock DW, Pahissa A, Rodriguez-Tudela JL. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55: 194-199.
44. Dannaoui E, Afeltra J, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 2002; 46: 2708-2711.
45. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-349.
46. Di Bonaventura G, Pompilio A, Picciani C, Allezzi M, D'Antonio D, Piccolomini R. Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance. Antimicrob Agents Chemother 2006; 50: 3269-3276.
47. Douglas LJ. Medical importance of biofilms in Candida infections. Rev Iberoam Micol 2002; 19: 139-143.
48. Espinel-Ingroff A, Arthington-Skaggs B, Iqbal N, Ellis D, Pfaller MA, Messer S, Rinaldi M, Fothergill A, Gibbs DL, Wang A. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. J Clin Microbiol 2007; 45: 1811-1820.
49. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, Pfaller MA, Rinaldi M, Rodriguez-Tudela JL, Verweij PE. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43: 3884-3889.
50. Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother 2007; 59: 767-771.
51. Fukuda T, Boeckh M, Guthrie KA, Mattson DK, Owens S, Wald A, Sandmaier BM, Corey L, Storb RF, Marr KA. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494-503.
52. García-Martos P, García-Agudo L, Gutiérrez-Calzada J, Ruiz-Aragón J, Saldarreaga A, Marin P. Actividad in vitro de anfotericina B, itraconazol y voriconazol frente a 20 especies de Aspergillus empleando el método de microdilución Sensititre®. Enferm Infecc Microbiol Clin 2005; 23: 15-18.
53. García-Tapia A, García-Agudo R, Marín P, Conejo JL, García-Martos P. Fungemia por Kodamaea (Pichia) ohmeri asociad a cirugía. Rev Iberoam Micol 2007; 24: 155-156.
54. Garau M, Pereiro M, del Palacio A. In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob Agents Chemother 2003; 47: 2342-2344.
55. Girmenia C, Pagano L, Martino B, D'Antonio D, Fanci R, Specchia G, Melillo L, Buelli M, Pizzarelli G, Venditti M, Martino P. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005; 43: 1818-1828.
56. Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother 2005; 55: 312-316.
57. Gualco L, Debbia EA, Bandettini R, Pescetto L, Cavallero A, Ossi MC, Schito AM, Marchese A. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults. Int J Antimicrob Agents 2007; 29: 179-184.
58. Guinea J, Pelaez T, Alcala L, Bouza E. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. Diagn Microbiol Infect Dis 2006; 56: 53-55.
59. Gutierrez J, Morales P, Gonzalez MA, Quindós G. Candida dubliniensis, a new fungal pathogen. J Basic Microbiol 2002; 42: 207-227.
60. Heyn K, Tredup A, Salvenmoser S, Muller FM. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005; 49: 5157-5159.
61. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biofilms and drug resistance. Emerg Infect Dis 2004; 10: 14-19.
62. Jabra-Rizk MA, Johnson JK, Forrest G, Mankes K, Meiller TF, Venezia RA. Prevalence of Candida dubliniensis fungemia at a large teaching hospital. Clin Infect Dis 2005; 41: 1064-1067.
63. Kale P, Johnson LB. Second-generation azole antifungal agents. Drugs Today (Barc) 2005; 41: 91-105.
64. Khan ZU, Randhawa HS, Kowshik T, Chowdhary A, Chandy R. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J Antimicrob Chemother 2007; en prensa.
65. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.
66. Krishnan S, Manavathu EK, Chandrasekar PH. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 2005; 55: 914-920.
67. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70: 878-888.
68. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-1780.
69. Lass-Florl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H, Freund M, Kropshofer G, Dierich MP, Nachbaur D. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201-207.
70. Lass-Florl C, Rief A, Leitner S, Speth C, Wurzner R, Dierich MP. In vitro activities of amphotericin B and voriconazole against aleurioconidia from Aspergillus terreus. Antimicrob Agents Chemother 2005; 49: 2539-2540.
71. Lewis RE, Wiederhold NP, Klepser ME. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother 2005; 49: 945-951.
72. Linares MJ, Solis F, Casal M. In vitro activity of voriconazole against Prototheca wickerhamii: comparative evaluation of sensititre and NCCLS M27-A2 methods of detection. J Clin Microbiol 2005; 43: 2520-2522.
73. MacCallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005; 49: 3697-3701.
74. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44: 529-535.
75. Mallie M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, Chandenier J, Cheuveau V, Couprie B, Datry A, Feuilhade M, Grillot R, Guiguen C, Lavarde V, Letscher V, Linas MD, Michel A, Morin O, Paugam A, Piens MA, Raberin H, Tissot E, Toubas D, Wade A. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study. Int J Antimicrob Agents 2005; 25: 321-328.
76. Marr KA. Invasive Candida infections: the changing epidemiology. Oncology 2004; 18: 9-14.
77. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.
78. Martinez LR, Casadevall A. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 2006; 50: 1021-1033.
79. Maschmeyer G, Haas A. Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections. Future Microbiology 2006; 1: 365-385.
80. Mellado E, Alcazar-Fuoli L, Garcia-Effron G, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med Mycol 2006; 44: 367-371.
81. Miranda KC, de Araujo CR, Costa CR, Passos XS, de Fatima Lisboa FO, do Rosario Rodrigues SM. Antifungal activities of azole agents against the Malassezia species. Int J Antimicrob Agents 2007; 29: 281-284.
82. Morace G, Polonelli L. Voriconazole activity against clinical yeast isolates: a multicentre Italian study. Int J Antimicrob Agents 2005; 26: 247-253.
83. Morera-Lopez Y, Torres-Rodriguez JM, Jimenez-Cabello T. Estudio de la sensibilidad in vitro de aislamientos clínicos de mohos y levaduras a itraconazol y voriconazol. Rev Iberoam Micol 2005; 22: 105-109.
84. Morera-Lopez Y, Torres-Rodriguez JM, Jimenez-Cabello T, Baro-Tomas T. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med Mycol 2005; 43: 505-510.
85. Muñoz P, Sanchez-Somolinos M, Alcala L, Rodriguez-Creixems M, Pelaez T, Bouza E. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 2005; 55: 188-193.
86. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
87. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. 2nd Ed. NCCLS document M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
88. National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeasts. Approved guidance. NCCLS document M44-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 2004.
89. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005; 41: 521-526.
90. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, Voltarelli JC, Colombo AL, Imhof A, Pasquini R, Maiolino A, Souza CA, Anaissie E. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237-1242.
91. O'Bryan TA. Pseudallescheriasis in the 21st century. Expert Rev Anti Infect Ther 2005; 3: 765-773.
92. O'shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother 2006; 58: 1168-1176.
93. Ortoneda M, Capilla J, Pastor FJ, Pujol I, Yustes C, Serena C, Guarro J. In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother 2004; 48: 2727-2729.
94. Panackal AA, Marr KA. Scedosporium/ Pseudallescheria infections. Semin Respir Crit Care Med 2004; 25: 171-181.
95. Passos XS, Costa CR, Araujo CR, Nascimento ES, Souza LK, Fernandes OF, Sales WS, Silva MR. Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital. Mycopathologia 2007; 163: 145-151.
96. Pelletier R, Alarie I, Lagace R, Walsh TJ. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 2005; 43: 559-564.
97. Pemán J, Cantón E, Calabuig E, Bosch M, Valenti A, Viudes A, Gobernado M. Actividad in vitro del voriconazol frente a levaduras y algas con los nuevos puntos de corte del patrón de resistencia. Rev Esp Quimioter 2006; 19: 21-33.
98. Pemán J, Cantón E, Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005; 24: 23-30.
99. Pemán J, Salvert M, Cantón E, Jarque I, Romá E, Zaragoza R, Viudes A, Gobernado M. Voriconazole in the management of nosocomial invasive fungal infections. Therapeutics and Clinical Risk Management 2006; 2: 1-30.
100. Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 2005; 56: 1144-1147.
101. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
102. Pfaller MA, Diekema DJ, Colombo AL, Kibbler C, Ng KP, Gibbs DL, Newell VA. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006; 44: 3578-3582.
103. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997-2005: An 8.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45: 1735-1745.
104. Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang SC, Gibbs DL, Newell VA. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006; 44: 3551-3556.
105. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, Chaturvedi V, Ghannoum MA, Odds FC, Rinaldi MG, Sheehan DJ, Troke P, Welsh TJ, Warnock DW. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819-826.
106. Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, Tiraboschi N, Nagy E, Gibbs DL. Results from the ARTEMIS DISK Globel Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43: 5848-5859.
107. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods. J Clin Microbiol 2007; 45: 70-75.
108. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Doern GV, Diekema DJ. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163-2167.
109. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142-3146.
110. Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005; 49: 3572-3574.
111. Pontón J, Quindós G. Mecanismos de resistencia a la terapéutica antifúngica. Med Clín (Barc) 2005; 125 (Supl. 1): 56-60.
112. Quindós G. New microbiological techniques for the diagnosis of invasive mycoses caused by filamentous fungi. Clin Microbiol Infect 2006; 12 (Supl. 7): 40-52.
113. Quindós G, Alkorta M, Rodríguez-Andrés C, Ullibarri B, Hernández-Almaraz JL. Epidemiological trends of candidemia in the tertiary-care hospital of Cruces, Barakaldo (Spain). The 16th Congress of the International Society for Human and Animal Mycology, Paris, 2006.
114. Quindós G, Carrillo-Muñoz AJ, Arévalo MP, Salgado J, Alonso-Vargas R, Rodrigo JM, Ruesga MT, Valverde A, Pemán J, Cantón E, Martín-Mazuelos E, Pontón J. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 2000; 46: 395-401.
115. Quindós G, Sánchez L, Villar M, Ahuad P, Eraso E, Hernández J. In vitro activities of fluconazole and voriconazole against Spanish bloodstream isolates of Candida glabrata and Candida krusei. 14th European Congress of Clinical Microbiology and Infectious Diseases. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Praga, 2004. Clin Microbiol Infect 2004; 10 (Supl. 3): 112-113.
116. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002; 49: 973-980.
117. Remage G, Martinez JP, Lopez-Ribot JL. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res 2006; 6: 979-986.
118. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: an update. Eukaryot Cell 2005; 4: 633-638.
119. Ramage G, Tomsett K, Wickes BL, Lopez-Ribot JL, Redding SW. Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 53-59.
120. Ramage G, Vande WK, Wickes BL, Lopez-Ribot JL. Biofilm formation by Candida dubliniensis. J Clin Microbiol 2001; 39: 3234-3240.
121. Ramage G, Vande WK, Wickes BL, Lopez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-2479.
122. Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 2001; 18: 163-170.
123. Ramage G, Wickes BL, Lopez-Ribot JL. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am Clin Lab 2001; 20: 42-44.
124. Ramos JM, Cuenca-Estrella M, Gutierrez F, Elia M, Rodriguez-Tudela JL. Clinical case of endocarditis due to Trichosporon inkin and antifungal susceptibility profile of the organism. J Clin Microbiol 2004; 42: 2341-2344.
125. Rementeria A, Sánchez-Vargas LO, Villar M, Casals JB, Carrillo-Muñoz AJ, Rodríguez AC, Eraso E, Quindós G. Comparison of tablet and disk diffusion methods for fluconazole and voriconazole in vitro activity testing against clinical yeast isolates. J Chemother 2007; 19: 172-177.
126. Revankar SG. Phaeohyphomycosis. Infect Dis Clin North Am 2006; 20: 609-620.
127. Revankar SG. Dematiaceous fungi. Mycoses 2007; 50: 91-101.
128. Ribeiro da Matta VL, Carvalho Melhem MS, Colombo AL, Moretti ML, Rodero L, Duboc de Almeida GM, Martins MA, Costa SF, Souza Dias MBG, Nucci M, Levin AS. Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. Antimicrob Agents Chemother 2007; 51: 1573-1576.
129. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56 (Supl 1): i5-i11.
130. Rodrigues AG, Araujo R, Pina-Vaz C. Interaction of local anaesthetics with other antifungal agents against pathogenic Aspergillus. Int J Antimicrob Agents 2006; 27: 339-343.
131. Rodriguez D, Almirante B, Park BJ, Cuenca-Estrella M, Planes AM, Sanchez F, Gene A, Xercavins M, Fontanals D, Rodriguez-Tudela JL, Warnock DW, Pahissa A. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006; 25: 224-229.
132. Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, Cano V, Tapia C, Perkins A, Gomez-Lopez A, Rodero L, Cuenca-Estrella M. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother 2005; 49: 4026-4034.
133. Rogers TR. Antifungal drug resistance: limited data, dramatic impact? Int J Antimicrob Agents 2006; 27: 7-11.
134. Rubio MC, de Ocariz I, Gil J, Benito R, Rezusta A. Potential fungicidal effect of voriconazole against Candida spp. Int J Antimicrob Agents 2005; 25: 264-267.
135. Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001; 39: 91-95.
136. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-2015.
137. Sahand IH, Moragues MD, Alhambra A, Del Palacio A, Quindós G, Ponton J. Isolation of Issatchenkia occidentalis from the esophagus of a leukemic patient. Rev Iberoam Micol 2006; 23: 235-237.
138. Salgado-Parreño FJ, Alcoba-Florez J, Arias A, Moragues MD, Quindós G, Pontón J, Arevalo MP. In vitro activities of voriconazole and five licensed antifungal agents against Candida dubliniensis: comparison of CLSI M27-A2, Sensititre YeastOne, disk diffusion, and Etest methods. Microb Drug Resist 2006; 12: 246-251.
139. San Miguel LG, Cobo J, Otheo E, Martos I, Muriel A, Fortun J, Moreno S. Candidemia in pediatric patients with congenital heart disease. Diagn Microbiol Infect Dis 2006; 55: 203-207.
140. San Miguel LG, Cobo J, Otheo E, Sanchez-Sousa A, Abraira V, Moreno S. Secular trends of candidemia in a large tertiary-care hospital from 1988 to
141. Sandven P. Epidemiology of candidemia. Rev Iberoam Micol 2000; 17: 73-81.
142. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: 1977-1981.
143. Sanz Alonso MA, Jarque I, Salavert M, Peman J. Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes. Clin Microbiol Infect 2006; 12: 2-6.
144. Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol 2006; 53: 121-126.
145. Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 2007; 51: 1818-1821.
146. Serena C, Fernandez-Torres B, Pastor FJ, Trilles L, Lazera MS, Nolard N, Guarro J. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother 2005; 49: 2994-2996.
147. Serena C, Marine M, Pastor FJ, Nolard N, Guarro J. In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J Antimicrob Chemother 2005; 55: 1020-1023.
148. Serena C, Pastor FJ, Marine M, Rodriguez MM, Guarro J. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother 2007; en prensa.
149. Shuford JA, Piper KE, Steckelberg JM, Patel R. In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates. Diagn Microbiol Infect Dis 2007;57:277-281.
150. Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del Busto R, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
151. Steinbach WJ, Benjamin DKJr, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-198.
152. Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates. Rev Iberoam Micol 2005; 22: 24-28.
153. Torres-Narbona M, Guinea J, Martinez-Alarcon J, Pelaez T, Bouza E. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother 2007; 51: 1126-1129.
154. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006; 27: 359-366.
155. Tortorano AM, Prigitano A, Biraghi E, Viviani MA. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production. J Antimicrob Chemother 2005; 56: 777-779.
156. van de Sande WW, Luijendijk A, Ahmed AO, Bakker-Woudenberg IA, van Belkum A. Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method. Antimicrob Agents Chemother 2005; 49: 1364-1368.
157. van Duin D, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 2004; 48: 2014-2020.
158. Wakiec R, Prasad R, Morschhauser J, Barchiesi F, Borowski E, Milewski S. Voriconazole and multidrug resistance in Candida albicans. Mycoses 2007; 50: 109-115.
159. Wern PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006; 57: 135-138.
160. Wynn RL, Jabra-Rizk MA, Meiller TF. Fungal drug resistance, biofilms, and new antifungals. Gen Dent 2003; 51: 94-98.
161. Zaoutis TE, Foraker E, McGowan KL, Mortensen J, Campos J, Walsh TJ, Klein JD. Antifungal susceptibility of Candida spp. isolated from pediatric patients: e survey of 4 children's hospitals. Diagn Microbiol Infect Dis 2005; 52: 295-298.
162. Zaragoza R, Peman J. Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy. Rev Iberoam Micol 2006; 23: 59-63.